The PReliminary Independent Model Advice (PRIMA) is available through the National Institute for Health and Clinical Excellence (NICE) Scientific Advice service, and gives pharmaceutical companies valuable feedback on their health economic models, which in turn can have a huge effect on a product’s passage through an HTA, for example. MAP Online explains PRIMA in detail here.
Launched in 2017, PRIMA is beginning to have a real impact on its users. This month, NICE have highlighted the story of Takeda, who have completed two separate projects with the PRIMA team. Takeda have found that not only is the service useful and efficient, they are able to influence future development of the service to make it even more useful. Using PRIMA has ensured that Takeda have appropriate models in place to ensure they present the best case to NICE in their HTA. Peter Wheatley-Price, Market Access and Pricing Director at Takeda UK Ltd, said:
“We appreciated the PRIMA team’s engaging and flexible approach at this pivotal stage in development and look forward to using the service as part of our model development going forward.”
NICE also point out that:
“The PRIMA service is open not only to models developed for future NICE technology appraisals but also to those developed for social care, public health, or in international settings In addition to cost-utility models, PRIMA can be used to quality assure cost-consequence, cost-minimisation, and budget impact models.”